| Sarah Bridge, MD | |
|
516 E Nizhoni Blvd, Gallup, NM 87301-5748 | |
| (505) 722-1000 | |
| Not Available |
| Full Name | Sarah Bridge |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 516 E Nizhoni Blvd, Gallup, New Mexico |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518459056 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MD2022-1465 (New Mexico) | Primary |
| Entity Name | Dhhs,phs,naihs, Gallup Indian Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225002322 PECOS PAC ID: 3173436409 Enrollment ID: O20031111000840 |
News Archive
Michail Sitkovsky, an immunophysiology expert at Northeastern University, and his research colleagues have made a breakthrough discovery in cancer treatment. The new approach, some 30 years in the making, could dramatically increase the survival rate of patients with cancer, which kills some 8 million people each year.
Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) today announced results from pivotal phase 3 studies of azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB), demonstrating greater 24-hour systolic blood pressure (SBP) reduction compared to commonly prescribed ARBs olmesartan medoxomil and valsartan.
Women with inherited mutations in the BRCA1 or BRCA2 genes are at substantially higher risk of breast cancer. For these women, effective prevention strategies are their best hope to reduce their breast cancer risk.
Researchers in the United States and Australia have conducted a comprehensive analysis of the epitope recognition patterns associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in humans.
› Verified 2 days ago
| Entity Name | Dhhs Phs Naihs Crownpoint Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114960093 PECOS PAC ID: 0143128041 Enrollment ID: O20031230000393 |
News Archive
Michail Sitkovsky, an immunophysiology expert at Northeastern University, and his research colleagues have made a breakthrough discovery in cancer treatment. The new approach, some 30 years in the making, could dramatically increase the survival rate of patients with cancer, which kills some 8 million people each year.
Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) today announced results from pivotal phase 3 studies of azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB), demonstrating greater 24-hour systolic blood pressure (SBP) reduction compared to commonly prescribed ARBs olmesartan medoxomil and valsartan.
Women with inherited mutations in the BRCA1 or BRCA2 genes are at substantially higher risk of breast cancer. For these women, effective prevention strategies are their best hope to reduce their breast cancer risk.
Researchers in the United States and Australia have conducted a comprehensive analysis of the epitope recognition patterns associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in humans.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Sarah Bridge, MD Po Box 1337, Gallup, NM 87305-1337 Ph: () - | Sarah Bridge, MD 516 E Nizhoni Blvd, Gallup, NM 87301-5748 Ph: (505) 722-1000 |
News Archive
Michail Sitkovsky, an immunophysiology expert at Northeastern University, and his research colleagues have made a breakthrough discovery in cancer treatment. The new approach, some 30 years in the making, could dramatically increase the survival rate of patients with cancer, which kills some 8 million people each year.
Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) today announced results from pivotal phase 3 studies of azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB), demonstrating greater 24-hour systolic blood pressure (SBP) reduction compared to commonly prescribed ARBs olmesartan medoxomil and valsartan.
Women with inherited mutations in the BRCA1 or BRCA2 genes are at substantially higher risk of breast cancer. For these women, effective prevention strategies are their best hope to reduce their breast cancer risk.
Researchers in the United States and Australia have conducted a comprehensive analysis of the epitope recognition patterns associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in humans.
› Verified 2 days ago
Mehdi Sattari, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: Rehoboth Mckinley Christian Health Care Services, 1901 Red Rock Drive, Gallup, NM 87301 Phone: 505-863-7000 | |
Alan Craig Beamsley, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 1010 Milda Ave, Gallup, NM 87301 Phone: 505-870-1256 | |
Faye Maryann Lee, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: Gimc Department Of Emergency Medicine, 516 Nizhoni Blvd, Gallup, NM 87301 Phone: 714-785-5263 | |
Alexander Miles Jenson, Emergency Medicine Medicare: Medicare Enrolled Practice Location: 516 E Nizhoni Blvd, Gallup, NM 87301 Phone: 781-301-1077 | |
Mac Henry, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 516 E Nizhoni Blvd, Gallup, NM 87301 Phone: 505-722-1000 | |
Clayton M Dalton, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 516 E Nizhoni Blvd, Gallup, NM 87301 Phone: 505-722-1000 | |
Darryl Macias, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: Rehoboth Mckinley Christian Health Care Services, 1901 Red Rock Drive, Gallup, NM 87301 Phone: 505-863-7000 |